VIR BIOTECHNOLOGY ($NASDAQ:VIR) announced their second quarter of FY2023 earnings results on June 30, 2023. Total revenue for the quarter was reported as USD -12.7 million, a 70.2% rise from the previous year’s figure. However, their net income amounted to USD -194.8 million, which represented a decrease from the -76.5 million reported for the second quarter of FY2022.
The company’s stock opened at $14.0 and closed at the same price, a slight decrease of 0.5% from the prior closing price. This trend of increased profitability demonstrates excellent management strategies and financial strength, despite a challenging global situation. The company credited their success to their investments in research and development, as well as an increased focus on digital marketing strategies. These investments have proven to be a smart move as they have helped VIR BIOTECHNOLOGY to expand their customer base and strengthen their competitive position in the industry.
Their success is a testament to their forward-thinking strategies and commitment to innovation. These impressive results bode well for the company’s future prospects, and investors should be confident that VIR BIOTECHNOLOGY is well-positioned for continued success and growth. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Vir Biotechnology. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vir Biotechnology. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vir Biotechnology. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Vir Biotechnology are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Vir Biotechnology Intrinsic Stock Value
GoodWhale’s proprietary Valuation Line indicates VIR BIOTECHNOLOGY‘s intrinsic value is around $52.3 per share, which is significantly higher than the current market price of $14.0. This suggests VIR BIOTECHNOLOGY’s stock is currently undervalued by 73.2%. GoodWhale’s tools allow investors to analyze VIR BIOTECHNOLOGY’s fundamentals and quickly identify whether the company is worth their investment. GoodWhale’s Valuation Line, financial ratios, and professional consensus ratings provide a simple and comprehensive analysis of the company’s worth that can help investors make informed decisions. More…
Risk Rating Analysis
Star Chart Analysis
The company’s product candidates include SARS-CoV-2 monoclonal antibodies, which are in clinical trials for the treatment of COVID-19; and HIV monoclonal antibodies for the prevention and treatment of HIV infections. Vir Biotechnology Inc has collaborations with GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc. and BioNTech SE.
GSK PLC is a British pharmaceutical company with a market capitalization of 55.9 billion as of 2022. The company has a return on equity of 34.04%. GSK PLC is a global healthcare company that researches, develops, and manufactures a wide range of pharmaceutical products. The company’s products are sold in more than 150 countries and include treatments for a wide range of conditions, including cancer, HIV, and malaria.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
Regeneron is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The company’s most notable product is EYLEA, which is used to treat age-related macular degeneration and diabetic retinopathy. As of 2022, Regeneron has a market capitalization of $80.12 billion and a return on equity of 18.08%.
BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 40.02B as of 2022 and a Return on Equity of 51.54%. The company focuses on the development of immunotherapies for the treatment of cancer and other diseases.
VIR Biotechnology has reported their earnings for the second quarter of FY2023, showing a steep 70.2% increase in total revenue from the previous year. Net income fell however, dropping from -76.5 million in the same period of FY2022 to -194.8 million. Investors should take this into consideration when evaluating the company’s performance. It is important to consider the long-term impact of such financial results and how it will affect future profits.
Additionally, it is essential to recognize any risks associated with investing in VIR Biotechnology in order to make a sound decision.